Vifor Pharma studies Ferinject in three trials for heart failure and iron deficiency

Swiss-based Vifor Pharma has initiated three clinical trials known as AFFIRM-AHF, FAIR-HF2 and HEART-FID, to assess the efficacy of Ferinject on morbidity and mortality outcomes in systolic heart failure and iron deficiency patients.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news